Market capitalization | $141.17m |
Enterprise Value | $-52.12m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 4.74 |
P/B ratio (TTM) P/B ratio | 0.65 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-21.23m |
Free Cash Flow (TTM) Free Cash Flow | $-10.99m |
Cash position | $193.35m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Eliem Therapeutics Inc:
1 Analyst has issued a forecast Eliem Therapeutics Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -21 -21 |
53%
53%
|
EBIT (Operating Income) EBIT | -21 -21 |
53%
53%
|
Net Profit | -69 -69 |
76%
76%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Redmond, WA.
Head office | United States |
CEO | Aoife Brennan |
Employees | 9 |
Founded | 2018 |
Website | www.climbbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.